Pinnacle Associates Ltd. Sells 36 Shares of Fresenius Medical Care Corporation (FMS)

Pinnacle Associates Ltd. decreased its holdings in shares of Fresenius Medical Care Corporation (NYSE:FMS) by 0.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,023 shares of the company’s stock after selling 36 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Fresenius Medical Care Corporation were worth $388,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Suntrust Banks Inc. raised its stake in Fresenius Medical Care Corporation by 17.7% during the first quarter. Suntrust Banks Inc. now owns 25,241 shares of the company’s stock valued at $1,062,000 after purchasing an additional 3,802 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Fresenius Medical Care Corporation by 27.9% during the first quarter. Bank of New York Mellon Corp now owns 49,250 shares of the company’s stock valued at $2,075,000 after purchasing an additional 10,751 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Fresenius Medical Care Corporation by 2.7% during the first quarter. JPMorgan Chase & Co. now owns 95,267 shares of the company’s stock valued at $4,013,000 after purchasing an additional 2,537 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Fresenius Medical Care Corporation by 13.9% during the first quarter. Dimensional Fund Advisors LP now owns 92,150 shares of the company’s stock valued at $3,882,000 after purchasing an additional 11,257 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in Fresenius Medical Care Corporation by 205.4% during the second quarter. SG Americas Securities LLC now owns 31,039 shares of the company’s stock valued at $1,500,000 after purchasing an additional 20,875 shares in the last quarter. 2.61% of the stock is currently owned by institutional investors.

FMS has been the topic of a number of recent research reports. Nord/LB reaffirmed a “buy” rating on shares of Fresenius Medical Care Corporation in a research note on Wednesday, June 28th. Royal Bank Of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, August 1st. DZ Bank AG reaffirmed a “neutral” rating on shares of Fresenius Medical Care Corporation in a research note on Monday, May 29th. BidaskClub downgraded shares of Fresenius Medical Care Corporation from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. Finally, Zacks Investment Research raised shares of Fresenius Medical Care Corporation from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research note on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $48.67.

Fresenius Medical Care Corporation (FMS) opened at 47.97 on Friday. The company has a market cap of $29.44 billion, a PE ratio of 21.12 and a beta of 0.48. Fresenius Medical Care Corporation has a 52-week low of $38.05 and a 52-week high of $50.22. The firm’s 50-day moving average is $46.79 and its 200-day moving average is $45.59.

Fresenius Medical Care Corporation (NYSE:FMS) last posted its quarterly earnings results on Tuesday, August 1st. The company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.53 by $0.05. Fresenius Medical Care Corporation had a return on equity of 11.57% and a net margin of 7.06%. The company had revenue of $4.47 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter in the prior year, the firm earned $0.96 EPS. The firm’s revenue was up 11.1% on a year-over-year basis. On average, equities research analysts anticipate that Fresenius Medical Care Corporation will post $2.35 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2017/09/10/pinnacle-associates-ltd-sells-36-shares-of-fresenius-medical-care-corporation-fms.html.

About Fresenius Medical Care Corporation

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Want to see what other hedge funds are holding FMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fresenius Medical Care Corporation (NYSE:FMS).

Institutional Ownership by Quarter for Fresenius Medical Care Corporation (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply